The Global Health Body Raises Concern Over Critical Lack of Obesity Jabs
Fewer than one in 10 patients who could benefit from weight-loss injections such as Wegovy have access to them, states the global health agency as it releases its initial recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for increased and just availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our new guidance affirms that excess weight is a chronic disease that can be treated with holistic and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key hurdles to broad availability to the jabs that can aid individuals in losing significant body mass, notes the body.
GLP-1 Therapy Scarcity
Even under the present most optimistic case, the manufacturing of these medications might only reach approximately 100 million people – fewer than 10% of the global need, according to the health organization.
The guideline calls on nations and manufacturers to expand access, by strategies including patent sharing.
Exclusive production rights on semaglutide – the core component of the drug Wegovy – is due to expire in a number of countries in 2026.
The Way Weight-Loss Drugs Work
The injections replicate a body's own hormone to slow digestion, curb appetite and boost feelings of fullness so people reduce food intake.
Individuals commonly see weight reduction after several weeks of starting on the once-weekly jabs.
Studies indicates patients may see weight return within a year of discontinuing the medication, because their usual appetite resume.
Being carrying excess weight raises your risk for developing health problems, including diabetes, heart disease, brain attack, and specific malignancies.
Obesity impacts people in all nations and was linked to millions of deaths worldwide in 2024, per the WHO.
